IONIS HTTRx

Drug Profile

IONIS HTTRx

Alternative Names: IONIS-HTTRx; ISIS 443139; ISIS-HTT Rx

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals; Roche
  • Developer Ionis Pharmaceuticals; Roche
  • Class Antisense oligonucleotides
  • Mechanism of Action HD protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease

Most Recent Events

  • 11 Dec 2017 Roche exercises the option to license IONIS HTTRx
  • 11 Dec 2017 Ionis Pharmaceuticals initiates enrolment in an open-label extension phase II trial in Huntington's disease in Canada, Germany and United Kingdom (NCT03342053)
  • 21 Nov 2017 Ionis Pharmaceuticals plans a phase II extension trial for Huntington's disease in Canada, Germany and United Kingdom (Intrathecal) in November 2017 (NCT03342053)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top